Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes

- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe . The FreeStyle Libre 3 technology provides continuous, real-time glucose readings automatically delivered to smartphones 2 every minute, offering unsurpassed 14-day accuracy 1 in the smallest and thinnest 3 sensor design at the same affordable price 7 as previous versions of the device.

Abbott's FreeStyle Libre 3 system features the world's smallest and thinnest wearable glucose sensor, which is about the size of two stacked U.S. pennies.

"Abbott won't stop innovating when there's room to raise the bar. We've done that again with FreeStyle Libre 3, the smallest sensor that delivers life-changing benefits and best-in-class accuracy," said Jared Watkin , senior vice president, Diabetes Care, Abbott. "People living with diabetes are at the center of our design process, and we made our next-generation technology even more discreet for a better user experience to make managing diabetes as easy and seamless as possible."

With a 14-day wear time, the FreeStyle Libre 3 system includes the longest-lasting, 9 self-applied CGM sensor available. The sensor is easy to apply 5 with a one-piece applicator and is worn on the back of the upper arm, eliminating the need for painful fingersticks 10 to view glucose levels.

To allow as many people as possible living with diabetes to access and benefit from the significant advancements of the technology, Abbott's FreeStyle Libre 3 system will be priced the same as previous generations of the device. 7

"Since we launched the first disposable glucose sensor in 2014, we've always believed all people with diabetes should have access to high-quality, accurate and affordable diabetes technologies," said Watkin. "That's why Abbott disrupted the traditional notion that CGMs have to sacrifice quality or accuracy for affordability, and we built our FreeStyle Libre family of products to deliver unparalleled results at a lower cost than any other CGM available."

The FreeStyle Libre 3 system fits seamlessly into the lives of people with diabetes. In addition to the sensor, the system includes the FreeStyle Libre 3 mobile app, 2 which is designed to enable users to capture and view their real-time glucose levels, glucose history and trend arrows showing how their glucose is changing with just a glance at their smartphone.

Abbott designed its next-generation FreeStyle Libre 3 system to be more sustainable for the environment with a smaller and more discreet sensor, reducing the total volume by more than 70%. 11 With a 41% reduction in plastic use and 43% reduction in carton paper, 11 the new sensor design aligns with the company's continued commitment to sustainability.

Abbott is launching the FreeStyle Libre 3 system in Europe in the coming months. The FreeStyle Libre portfolio has been clinically proven to improve glucose control, 12 increase time in target glucose range, 13 decrease time in hyperglycemia (high glucose levels) and hypoglycemia (low glucose levels), 14 and lower HbA1c (average glucose levels over a three-month period) 12 – all factors contributing to better health outcomes. Data also show use of the FreeStyle Libre system reduces diabetes-related hospital admissions and work absentee rates to help improve quality of life. 15

As the #1 sensor-based glucose monitoring system used in the U.S. and worldwide, 8 Abbott's FreeStyle Libre portfolio has changed the lives of more than 2 million people across more than 50 countries 5 by providing breakthrough technology that is accessible and affordable. 7 Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 37 countries, including Canada, France, Germany, Japan, the United Kingdom and the U.S.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

1 Alva, Shridhara, Timothy Bailey , Ronald Brazg , Erwin S. Budiman , Kristin Castorino , Mark P. Christiansen , Gregory Forlenza , Mark Kipnes , David R. Liljenquist , and Hanqing Liu . "Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes." Journal of Diabetes Science and Technology, ( September 2020 ). https://doi.org/10.1177/1932296820958754 .
2 The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems.
3 Among patient-applied sensors. Data on File, Abbott Diabetes Care.
4 Among on-body sensors. Data on File, Abbott Diabetes Care.
5 Data on file. Abbott Diabetes Care.
6 60-minute warm-up required when starting the sensor.
7 Based on a comparison of list prices of the FreeStyle Libre portfolio versus competitor CGM systems available worldwide. The actual cost to patients may or may not be lower than other CGM systems, depending on local reimbursement, if any.
8 Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre portfolio compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
9 Among leading CGM brands. Data on File, Abbott Diabetes Care.
10 Finger pricks are required if glucose readings do not match symptoms or expectations.
11 Compared to other FreeStyle Libre systems; Data on file, Abbott Diabetes Care.
12 Eeg-Olofsson et al. Sustainable HbA1c decrease at 12 months for adults with Type 1 and Type 2 Diabetes using the FreeStyle Libre System: a study within the National Diabetes Register in Sweden.
13 Lang J, Jangam SR, Dunn TC, Hayter G. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control.
14 Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37-46.
15 Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diab Res Care. 2019;7(1):e000809. doi:10.1136/bmjdrc-2019-000809.

Abbott's FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings directly to smartphones for people with diabetes.

Abbott, the worldwide leader in continuous glucose monitoring technology, has secured CE Mark for its next-generation FreeStyle Libre 3 system for people with diabetes.

Abbott Logo (PRNewsFoto/Abbott)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/abbotts-freestyle-libre-3-system-receives-ce-mark--features-worlds-smallest-thinnest-sensor-with-best-in-class-performance-at-the-same-low-cost-for-people-with-diabetes-301138719.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×